cCAM Biotherapeutics Announced Today the Completion of its Series A Financing
TEL HAI, Israel, September 14, 2012 /PRNewswire/ –
cCAM Biotherapeutics [http://www.ccam-bio.com ], a biopharmaceutical company focused
on the discovery and development of novel immunomodulatory drugs for cancer, announced
today the completion of its Series A financing . The round was led by Arkin Holdings and
included participation from OrbiMed’s Israel Partners, Pontifax and F.Hoffmann La Roche.
cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for
cancer. cCAM’s lead agent, CM-10, is an immunomodulatory humanized monoclonal antibody
that harnesses the patient’s immune system to attack tumors. CM-10 targets CEACAM1
[http://en.wikipedia.org/wiki/CEACAM1 ], a receptor newly characterized as an immune
checkpoint used by cancer cells to suppress the immune system. Upon binding to CEACAM1,
CM-10 leads to a cancer specific immune response.
“We are very pleased to expand our circle of industry-leading investors,” said Dr.
Tehila Ben Moshe, cCAM Bio’s CEO. “With our series A complete, we are in a position to
advance our lead antibody through a proof of concept study in humans.”
Contact details: Tehila Ben-Moshe, Ph.D CEO cCAM Biotherapeutics Ltd. Tel: +1(972)-4-9534651, +1(972)-52-3319649 email: email@example.com
SOURCE cCAM Biotherapeutics Ltd